-
Mashup Score: 0
Percent-predicted FEV1 and respiratory-related quality of life improved with 28-day triple therapy in individuals with the N1303K cystic fibrosis transmembrane conductance defect, according to data published in Lancet Respiratory Medicine.“CFTR modulators are approved for approximately 90% of people with cystic fibrosis in the [United States] and provide substantial clinical benefit,”
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 1Low testosterone levels found in one-quarter of CF men in study - 4 month(s) ago
About one-quarter of men with cystic fibrosis have low testosterone levels, a study into the prevalence of this sexual health issue found.
Source: cysticfibrosisnewstoday.comCategories: General Medicine News, EndocrinologyTweet-
Paper from the @emoryhealthcare #CysticFibrosis Program published in @AJMSonline About one-quarter of men with cystic fibrosis have low testosterone levels, a study into the prevalence of this sexual health issue found. https://t.co/6UU3YMGD7E
-
-
Mashup Score: 0Q&A: Finding a treatment for rare cystic fibrosis splicing mutation - 4 month(s) ago
Although inhaled antisense oligonucleotide treatment is safe, its efficacy needs to be determined in patients with the cystic fibrosis splicing mutation 3849+10kb C-to-T, according to a press release from the Cystic Fibrosis Foundation.In an effort to uncover how this drug performs in this specific patient population, SpliSense is conducting a phase 2 trial on its antisense oligonucleotide (ASO)
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
To uncover how antisense oligonucleotide performs in patients with the #cysticfibrosis splicing mutation 3849+10kb C-to-T, SpliSense is conducting a phase 2 trial. 🗨️Healio spoke with @stevenmrowe, MD, of the @CF_Foundation, to learn more. Read more🔽 https://t.co/PUucjQ139v
-
-
Mashup Score: 0Q&A: Finding a treatment for rare cystic fibrosis splicing mutation - 5 month(s) ago
Although inhaled antisense oligonucleotide treatment is safe, its efficacy needs to be determined in patients with the cystic fibrosis splicing mutation 3849+10kb C-to-T, according to a press release from the Cystic Fibrosis Foundation.In an effort to uncover how this drug performs in this specific patient population, SpliSense is conducting a phase 2 trial on its antisense oligonucleotide (ASO)
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
To uncover how antisense oligonucleotide performs in patients with the #cysticfibrosis splicing mutation 3849+10kb C-to-T, SpliSense is conducting a phase 2 trial. 🗨️Healio spoke with @stevenmrowe, MD, of the @CF_Foundation, to learn more. Read more🔽 https://t.co/PUucjQ139v
-
-
Mashup Score: 0Q&A: Finding a treatment for rare cystic fibrosis splicing mutation - 5 month(s) ago
Although inhaled antisense oligonucleotide treatment is safe, its efficacy needs to be determined in patients with the cystic fibrosis splicing mutation 3849+10kb C-to-T, according to a press release from the Cystic Fibrosis Foundation.In an effort to uncover how this drug performs in this specific patient population, SpliSense is conducting a phase 2 trial on its antisense oligonucleotide (ASO)
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
To uncover how antisense oligonucleotide performs in patients with the #cysticfibrosis splicing mutation 3849+10kb C-to-T, SpliSense is conducting a phase 2 trial. 🗨️Healio spoke with @stevenmrowe, MD, of the @CF_Foundation, to learn more. Read more🔽 https://t.co/PUucjQ139v
-
-
Mashup Score: 7Q&A: Genetic technologies aim to advance cystic fibrosis treatments - 10 month(s) ago
In patients with cystic fibrosis, a new genetic technology could permanently fix the CF transmembrane conductance regulator gene in hundreds of disease-causing CF mutations, according to a press release from the Cystic Fibrosis Foundation.Prime Medicine is conducting research on what is known as gene editing in CF, thanks in part to funding from the Cystic Fibrosis Foundation.
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
💬Healio spoke with Steven M. Rowe, MD, executive vice president and chief scientific officer of the @CF_Foundation, to learn more about gene editing and how research 🔬 in this area could advance #cysticfibrosis treatments. Read more ⬇️ https://t.co/wk5PZmKxM8 @stevenmrowe
-
-
Mashup Score: 7Q&A: Genetic technologies aim to advance cystic fibrosis treatments - 10 month(s) ago
In patients with cystic fibrosis, a new genetic technology could permanently fix the CF transmembrane conductance regulator gene in hundreds of disease-causing CF mutations, according to a press release from the Cystic Fibrosis Foundation.Prime Medicine is conducting research on what is known as gene editing in CF, thanks in part to funding from the Cystic Fibrosis Foundation.
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
💬Healio spoke with Steven M. Rowe, MD, executive vice president and chief scientific officer of the @CF_Foundation, to learn more about gene editing and how research 🔬 in this area could advance #cysticfibrosis treatments. Read more ⬇️ https://t.co/wk5PZmKxM8 @stevenmrowe
-
-
Mashup Score: 1Parental Feeding Style, Parenting Stress, and Child Mealtime Behaviors in Cystic Fibrosis - 10 month(s) ago
AbstractObjective. Nutrition and weight gain significantly contribute to overall health outcomes in children with cystic fibrosis (CF). Strong emphasis is place
Source: academic.oup.comCategories: General Medicine News, PediatricsTweet-
January Issue: New research links authoritarian parental feeding style with more problematic mealtime behaviors and stress for parents of children with #cysticfibrosis. New study explores benefits of using a parental feeding style measure in CF clinic. https://t.co/pDMZZ4Lwxd
-
-
Mashup Score: 16Atrium Health Levine Children's on LinkedIn: New year, new accreditation, same incredible team! You’re looking at… - 11 month(s) ago
New year, new accreditation, same incredible team! You’re looking at our talented pulmonology team who is responsible for Atrium Health Levine Children’s…
Source: www.linkedin.comCategories: General Medicine News, Future of MedicineTweet-
Congratulations to @AtriumHealth @LevineChildrens pulmonology team who received full accreditation from the #CysticFibrosis Foundation. What a fantastic way to start the new year! 🎊 https://t.co/dcpoRwa23B
-
-
Mashup Score: 5A Cross-Sectional Study of Pediatric Feeding Disorder in... : Journal of Pediatric Gastroenterology and Nutrition - 11 month(s) ago
d to categorize feeding dysfunction across various domains in children with CF. Methods: An observational cross-sectional study was conducted in children with CF. Data collected included anthropometrics, nutrition data (including need for tube feeding/enteral nutrition [EN] or high-energy beverages, dietary diversity), feeding skills (Pediatric version of the Eating Assessment tool [pEAT]), and psychosocial function (About Your Child’s Eating questionnaire [AYCE] in children 2–17 years of age/Behavioral Pediatric Feeding Assessment Scale [BPFAS] in children 12–23 months of age). PFD was defined as poor oral intake with: (a) pEAT score > 5; and/or (b) AYCE or BPFAS score > 2 standard deviation of normative controls; and/or (c) nutrition dysfunction (body mass index/weight-for-length z score < −1 and/or preference of oral high energy beverages or dependence on EN and/or decreased dietary diversity). Results: Of 103 children in the study, 62 (60.1%) had PFD, 7 children (6.8%) were malnour
Source: journals.lww.comCategories: General Medicine News, PediatricsTweet-
Bashir et al review pediatric feeding disorder in children with #cysticfibrosis, finding that nearly 2/3 of children with CF have pediatric feeding disorder. https://t.co/27ftT2iLYL https://t.co/AssCJaK5ag
-
Percent-predicted FEV1 and respiratory-related quality of life improved with 28-day triple therapy in individuals with the N1303K #cysticfibrosis transmembrane conductance defect, said Dr. George M. Solomon of @UABNews. @TheLancet Read more 👇 https://t.co/yLF9XZrav4